Business
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
OSAKA, Japan, April 08, 2026--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has been awarded a contract through the Biomedical Advanced Research and Development Authority’s (BARDA) Project BioShield related to Fetroja® (cefiderocol) as a critical countermeasure against difficult-to-treat Gram-negative bacterial infections and pathogens that present a h
About this update from Shionogi & Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":385,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/c4655fadca6904d799488381d7190886"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OxS1pt1SmtZeFUx_J.Vi6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTg3OQ--/https://media.zenfs.com/en/business-wire.com/c4655fadca6904d799488381d7190886","width":385,"height":480}},"lazy":false},{"type":"text","content":"Program Includes Establishing Pharmaceutical Manufacturing in the U.S., Procurement and Development of Treatment for Infections Caused by Biothreat Pathogens","length":157,"tagName":"p","attribs":{}},{"type":"text","content":"OSAKA, Japan, April 08, 2026--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has been awarded a contract through the Biomedical Advanced Research and Development Authority’s (BARDA) Project BioShield related to Fetroja® (cefiderocol) as a critical countermeasure against difficult-to-treat Gram-negative bacterial infections and pathogens that present a high-priority biothreat to national health security. The contract is initially funded at $119 million with multiyear options for a total of up to $482 million.","length":689,"tagName":"p"},{"type":"text","content":"The contract will bolster the U.S. government’s ability to respond to national health security threats and strengthen domestic manufacturing capabilities and supply readiness by funding Shionogi Inc. to:","length":203,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Establish a U.S. drug product manufacturing site for Fetroja.","length":61,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Support procurement of Fetroja.","length":31,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Advance Fetroja for the treatment of infections caused by high priority biothreat pathogens, including Burkholderia pseudomallei (melioidosis) and Yersinia pestis (plague).","length":172,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Expand the utility of Fetroja for HABP/VABP in pediatric patients with a U.S. Food and Drug Administration (FDA...